Patents by Inventor Teruo Nakamura

Teruo Nakamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10501369
    Abstract: A translucent substrate includes a glass substrate containing at least one element selected from a group consisting of Bi, Ti and Sn; a coating layer formed on the glass substrate; and a transparent conductive film formed on the coating layer, wherein the coating layer is deposited by a dry depositing method.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: December 10, 2019
    Assignee: AGC Inc.
    Inventors: Takahiro Mashimo, Naoto Kihara, Kazunobu Maeshige, Teruo Fujiwara, Masahiro Kishi, Nobuhiro Nakamura, Mamoru Isobe
  • Publication number: 20190142959
    Abstract: The present invention provides hyaluronic acid derivatives into which a certain cationic group and a certain hydrophobic group are introduced, the hyaluronic acid derivatives including one or more repeating units represented by the formula (Ia) and one or more repeating units represented by the formula (Ib).
    Type: Application
    Filed: May 11, 2017
    Publication date: May 16, 2019
    Inventors: Takashi NAKAI, Teruo NAKAMURA, Sayan CHUANOI, Hideyuki TOGAWA, Tsuyoshi SHIMOBOJI, Kazuo HATTORI, Takashi EMURA
  • Patent number: 10235658
    Abstract: The maintenance management device 3 includes an error status diagnosis unit 11, a grace period estimation unit 14, a maintenance cost estimation unit 15, and a screen display unit 17. When the error status diagnosis unit 11 has diagnosed the occurrence of an anomaly, the grace period estimation unit 14 estimates a first grace period leading up to the occurrence of a failure. The maintenance cost estimation unit 15 estimates the cost of corrective maintenance incurred when the failure occurs after the elapse of the first grace period. The screen display unit 17 displays a combination of the first grace period and the cost of corrective maintenance. Alternatively, the grace period estimation unit 14 estimates a second grace period over which preventive maintenance may be postponed without a failure.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: March 19, 2019
    Assignee: Hitachi Construction Machinery Co., Ltd.
    Inventors: Hideaki Suzuki, Kozo Nakamura, Shinya Yuda, Munetoshi Unuma, Junsuke Fujiwara, Takayuki Uchida, Katsuaki Tanaka, Mitsuo Aihara, Teruo Nakamura, Nobuyoshi Hirowatari, Hiroshi Ogura
  • Patent number: 10087605
    Abstract: A diagnostic system for a work machine includes a data storage device (210) in which sensor information (A) input from a sensor (101A) that senses an oil property of oil used for operation of the work machine and an abnormality degree determination value defined for each kind of the sensor information (A) are stored, and an arithmetic processing device (104) that executes first processing of discriminating the degree of abnormality level of the oil based on the sensor information (A) and the abnormality degree determination value, second processing of determining whether or not necessity to carry out oil analysis involving oil extraction exists based on the degree of abnormality level of the oil discriminated in the first processing, and third processing of outputting information indicating that the oil analysis is necessary to other terminal if it is determined that the oil analysis is necessary in the second processing.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: October 2, 2018
    Assignee: Hitachi Construction Machinery Co., Ltd.
    Inventors: Teruo Nakamura, Akira Kurasako, Hideki Akita, Yoshiya Hamamachi, Katsutoshi Hakozaki, Kotaro Ogura
  • Publication number: 20170284068
    Abstract: A diagnostic system for a work machine includes a data storage device (210) in which sensor information (A) input from a sensor (101A) that senses an oil property of oil used for operation of the work machine and an abnormality degree determination value defined for each kind of the sensor information (A) are stored, and an arithmetic processing device (104) that executes first processing of discriminating the degree of abnormality level of the oil based on the sensor information (A) and the abnormality degree determination value, second processing of determining whether or not necessity to carry out oil analysis involving oil extraction exists based on the degree of abnormality level of the oil discriminated in the first processing, and third processing of outputting information indicating that the oil analysis is necessary to other terminal if it is determined that the oil analysis is necessary in the second processing.
    Type: Application
    Filed: October 20, 2015
    Publication date: October 5, 2017
    Inventors: Teruo NAKAMURA, Akira KURASAKO, Hideki AKITA, Yoshiya HAMAMACHI, Katsutoshi HAKOZAKI, Kotaro OGURA
  • Patent number: 9394379
    Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: July 19, 2016
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kenji Yasugi, Teruo Nakamura, Tsuyoshi Shimoboji, Mika Sato
  • Publication number: 20150206104
    Abstract: The maintenance management device 3 includes an error status diagnosis unit 11, a grace period estimation unit 14, a maintenance cost estimation unit 15, and a screen display unit 17. When the error status diagnosis unit 11 has diagnosed the occurrence of an anomaly, the grace period estimation unit 14 estimates a first grace period leading up to the occurrence of a failure. The maintenance cost estimation unit 15 estimates the cost of corrective maintenance incurred when the failure occurs after the elapse of the first grace period. The screen display unit 17 displays a combination of the first grace period and the cost of corrective maintenance. Alternatively, the grace period estimation unit 14 estimates a second grace period over which preventive maintenance may be postponed without a failure.
    Type: Application
    Filed: July 10, 2013
    Publication date: July 23, 2015
    Inventors: Hideaki Suzuki, Kozo Nakamura, Shinya Yuda, Munetoshi Unuma, Junsuke Fujiwara, Takayuki Uchida, Katsuaki Tanaka, Mitsuo Aihara, Teruo Nakamura, Nobuyoshi Hirowatari, Hiroshi Ogura
  • Patent number: 8862390
    Abstract: To advance a dump truck quickly and smoothly to a position where target loading work will be performed relative to an excavating machine, the dump truck is placed in loading target position relative to the excavating machine. Geographic position is detected from GPS satellites of a GPS receiver of the dump truck. The position and direction of the geographic position is transmitted to the excavating machine as a target position image. The target position image and an approach route leading to the position are displayed on a dump truck display when the truck thereafter approaches the position. The dump truck thereafter approaches the position, and the truck is driven so that a current position image advances along the approach route to the target position image, whereby the dump truck is placed in the set loading image target position.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: October 14, 2014
    Assignee: Hitachi Construction Machinery Co., Ltd.
    Inventors: Kazuhiro Sugawara, Hiroshi Ogura, Katsuaki Tanaka, Teruo Nakamura
  • Publication number: 20140019042
    Abstract: To advance a dump truck quickly and smoothly to a position where target loading work will be performed relative to an excavating machine, the dump truck is placed in loading target position relative to the excavating machine. Geographic position is detected from GPS satellites of a GPS receiver of the dump truck. The position and direction of the geographic position is transmitted to the excavating machine as a target position image. The target position image and an approach route leading to the position are displayed on a dump truck display when the truck thereafter approaches the position. The dump truck thereafter approaches the position, and the truck is driven so that a current position image advances along the approach route to the target position image, whereby the dump truck is placed in the set loading image target position.
    Type: Application
    Filed: March 27, 2012
    Publication date: January 16, 2014
    Applicant: Hitachi Construction Machinery Co., Ltd.
    Inventors: Kazuhiro Sugawara, Hiroshi Ogura, Katsuaki Tanaka, Teruo Nakamura
  • Publication number: 20140011991
    Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.
    Type: Application
    Filed: July 22, 2013
    Publication date: January 9, 2014
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kenji YASUGI, Teruo NAKAMURA, Tsuyoshi SHIMOBOJI, Mika SATO
  • Publication number: 20120183567
    Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.
    Type: Application
    Filed: March 26, 2012
    Publication date: July 19, 2012
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kenji YASUGI, Teruo NAKAMURA, Tsuyoshi SHIMOBOJI, Mika SATO
  • Patent number: 8143391
    Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: March 27, 2012
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kenji Yasugi, Teruo Nakamura, Tsuyoshi Shimoboji, Mika Sato
  • Patent number: 8022191
    Abstract: The present invention provides a polyethylene glycol-conjugated erythropoietin (PEG-conjugated EPO) prepared by PEG conjugation on the lysine residue at position 52 of native erythropoietin (native EPO). In order to achieve more sustained efficacy without losing physiological activities of native EPO, a glycoprotein rich in sugar chains, there has been a need to develop a PEG-conjugated EPO with significantly sustained efficacy by introducing a controlled number of PEG molecules at controlled positions. This PEG-conjugated EPO addresses such a need and provides more sustained efficacy.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: September 20, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Teruo Nakamura, Yasuo Sekimori, Minoru Machida, Hiromitsu Kawata, Hajime Miyamoto
  • Patent number: 7816316
    Abstract: The present invention aims to provide completely biodegradable and biocompatible sustained-release carriers for proteins or peptides, which allow encapsulation of the proteins or peptides at high encapsulation rates without inhibiting their biological activity. The present invention provides a method for preparing a sustained-release carrier, wherein in a solution in the presence of a protein or a peptide, a hyaluronic acid derivative having an unsaturated bond(s) or a mercapto group(s) introduced into hyaluronic acid is chemically crosslinked with a mercapto group-containing compound or an unsaturated bond-containing compound, respectively, to give a hydrogel. The method of the present invention enables efficient encapsulation of proteins or peptides while retaining their biological activity.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: October 19, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Sei Kwang Hahn, Teruo Nakamura, Tsuyoshi Shimoboji
  • Patent number: 7767806
    Abstract: A hyaluronic acid modification product includes a polymer bonded to hyaluronic acid, the polymer being polylactic acid, polyglycolic acid or lactic acid-glycolic acid copolymer, providing a drug carrier which efficiently encapsulates low molecular weight drugs and provides sustained-release over a long term, control of blood residence, is well dispersible in an aqueous solution, and has excellent biocompatibility.
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: August 3, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tai Hirakura, Teruo Nakamura, Tsuyoshi Shimoboji
  • Publication number: 20090193826
    Abstract: There is provided a temperature switching compartment 3 which can switch the internal temperature thereof between a low temperature side at which a storage material is kept in cold storage and a high temperature side maintained at 50° C., to 80° C. at which cooked food is kept warm, by cooling with a cooler 17 and heating with a heater 15.
    Type: Application
    Filed: September 7, 2005
    Publication date: August 6, 2009
    Inventors: Kenji Yasugi, Teruo Nakamura, Tsuyoshi Shimoboji, Mika Sato
  • Publication number: 20090148534
    Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction rate of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction rate as that of the conventionally known gel.
    Type: Application
    Filed: September 7, 2005
    Publication date: June 11, 2009
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kenji Yasugi, Teruo Nakamura, Tsuyoshi Shimoboji, Mika Sato
  • Publication number: 20090082266
    Abstract: To provide a GLP-1 analogue long-acting prophylactic or therapeutic agent for diabetes, diabetic complications and/or obesity due to diabetes which provides an extended half-life of a GLP-1 analogue in the blood to prevent frequent administration, and is biodegradable and safe. The present invention provides a conjugate obtained by binding, to a GLP-1 analogue into which a mercapto group is incorporated, water soluble hyaluronic acid modification product obtained by incorporating a substituent via an amide bond to the carboxyl group of glucuronic acid portion of hyaluronic acid as a derivative thereof, using a specific condensing agent in an aprotic polar solvent; and a prophylactic or therapeutic agent having a durable blood glucose lowering effect for diabetes, diabetic complications or obesity.
    Type: Application
    Filed: March 8, 2006
    Publication date: March 26, 2009
    Inventors: Teruo Nakamura, Tatsuya Kato, Hideyuki Togawa, Kenji Yasugi, Hiroko Konishi, Yasuo Sekimori, Tsuyoshi Shimoboji
  • Publication number: 20070031503
    Abstract: There is provided a drug carrier which has solved the problems of conventional drug carriers, which can encapsulate a low molecular drug efficiently, which can control a sustained release period for a long term, which can control blood residence, which has high dispersibility in an aqueous solution, and which is not problematical in safety. A drug carrier, which comprises injectable fine particles minimal in agglomeration between the particles, and which has excellent biocompatibility, is also provided.
    Type: Application
    Filed: September 8, 2004
    Publication date: February 8, 2007
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tai Hirakura, Teruo Nakamura
  • Publication number: 20060276634
    Abstract: The present invention provides a polyethylene glycol-conjugated erythropoietin (PEG-conjugated EPO) prepared by PEG conjugation on the lysine residue at position 52 of native erythropoietin (native EPO). In order to achieve more sustained efficacy without losing physiological activities of native EPO, a glycoprotein rich in sugar chains, there has been a need to develop a PEG-conjugated EPO with significantly sustained efficacy by introducing a controlled number of PEG molecules at controlled positions. This PEG-conjugated EPO addresses such a need and provides more sustained efficacy.
    Type: Application
    Filed: August 3, 2006
    Publication date: December 7, 2006
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Teruo Nakamura, Yasuo Sekimori, Minoru Machida, Hiromitsu Kawata, Hajime Miyamoto